HFS
RAPT

Hughes Financial Services’s RAPT Therapeutics RAPT Stock Holding History

Hughes Financial Services’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-41
Closed -$383 – 1193
2025
Q1 		$383 Buy
+41
New +$403 ﹤0.01% 1018

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Hughes Financial Services's RAPT Position: Q2 2025 in Review

Hughes Financial Services sold out of RAPT Therapeutics (RAPT) in Q2 2025, closing a stake of 41 shares — an estimated $383 sold.

Hughes Financial Services first reported a position in RAPT in Q1 2025 and held it in 1 quarter. The position peaked at $383 in Q1 2025. 50 funds tracked by Wall St. Rank hold RAPT as of Q2 2025.

  • Hughes Financial Services reported no remaining RAPT Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hughes Financial Services sold 41 RAPT Therapeutics shares in Q2 2025, an estimated $383.
  • Hughes Financial Services first reported a position in RAPT Therapeutics in Q1 2025 and held it in 1 quarter.
  • Hughes Financial Services's RAPT Therapeutics position peaked at $383 in Q1 2025.
  • 50 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2025.

Based on Hughes Financial Services's 13F filing for Q2 2025, filed 7 Aug 2025.